Royalty Pharma plc Files 8-K Report

TL;DR

Royalty Pharma filed a routine 8-K, no major news.

AI Summary

On May 29, 2024, Royalty Pharma plc filed an 8-K report. The filing primarily serves as a notification of other events, with no specific material transactions or financial updates detailed in the provided text. The company's principal executive offices are located at 110 East 59th Street, New York, NY 10022.

Why It Matters

This 8-K filing indicates a routine update or notification from Royalty Pharma plc to the SEC, without disclosing specific material events that would immediately impact investors.

Risk Assessment

Risk Level: low — The filing is a standard 8-K report for 'Other Events' and does not contain information about significant financial changes, acquisitions, or legal issues.

Key Players & Entities

• Royalty Pharma plc (company) — Registrant
• May 29, 2024 (date) — Date of Report
• 110 East 59th Street, New York, NY 10022 (location) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.0001 — red Class A Ordinary Shares, par value $0.0001 per share RPRX The Nasdaq Stock Mar
• $1 billion — non-risk adjusted peak sales of between $1 billion and $5 billion. Forward-Looking State
• $5 billion — ed peak sales of between $1 billion and $5 billion. Forward-Looking Statements The inf

Filing Documents

• d34372d8k.htm (8-K) — 27KB
• 0001193125-24-149338.txt ( ) — 144KB
• rprx-20240529.xsd (EX-101.SCH) — 3KB
• rprx-20240529_lab.xml (EX-101.LAB) — 17KB
• rprx-20240529_pre.xml (EX-101.PRE) — 11KB
• d34372d8k_htm.xml (XML) — 4KB

Forward-Looking Statements

Forward-Looking Statements The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this Form 8-K unless stated otherwise, and neither the delivery of this Form 8-K at any time, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof. This Form 8-K contains statements that constitute "forward-looking statements" as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the Company's opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of our strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as "may," "might," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "target," "forecast," "guidance," "goal," "predicts," "project," "potential" or "continue," the negative of these terms or similar expressions. Forward-looking statements are based on management's current beliefs and assumptions and on information currently available to the Company. However, these forward-looking statements are not a guarantee of our performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, and other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of thes

SIGNATURES

SIGNATURES Pursuant to the requirement of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ROYALTY PHARMA PLC Date: May 29, 2024 By: /s/ Terrance Coyne Terrance Coyne Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR